Stay updated with breaking news from Jay Venkatesan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Elicio Therapeutics dipped its toe in the IPO waters but decided to go public by merging with publicly traded Angion Biomedica. Clinical-stage Elicio is developing immunotherapies, including cancer vaccines, that work by targeting immune cells located in the lymph nodes.
Angion Biomedica Corp. discontinued a Phase II kidney disease trial while Novo Nordisk missed the mark in a NASH study.
Angion Biomedica (NASDAQ:ANGN – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, “Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel […]
Interview with Jay Venkatesan, M.D., the President, Chief Executive Officer, and Chairman of Angion Biomedica Corp. (ANGN).
Press release content from Globe Newswire. The AP news staff was not involved in its creation.